Skip to Content

Tolvaptan

Medically reviewed on Sep 10, 2018

Pronunciation

(tol VAP tan)

Index Terms

  • OPC-41061

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Samsca: 15 mg, 30 mg [contains fd&c blue #2 aluminum lake]

Tablet Therapy Pack, Oral:

Jynarque: 45 & 15 MG (14 ea); 60 & 30 MG (14 ea); 90 & 30 MG (14 ea) [contains corn starch, fd&c blue #2 aluminum lake]

Brand Names: U.S.

  • Jynarque
  • Samsca

Pharmacologic Category

  • Vasopressin Antagonist

Pharmacology

An arginine vasopressin (AVP) receptor antagonist with affinity for AVP receptor subtypes V2 and V1a in a ratio of 29:1. Antagonism of the V2 receptor by tolvaptan promotes the excretion of free water (without loss of serum electrolytes) resulting in net fluid loss, increased urine output, decreased urine osmolality, and subsequent restoration of normal serum sodium levels.

Distribution

Vd: ~3 L/kg

Metabolism

Almost exclusively hepatic via CYP3A4 (none are pharmacodynamically active)

Excretion

Feces: 59% (19% as unchanged drug); Urine: 40% (<1% as unchanged drug)

Onset of Action

Aquaretic and sodium increasing effects (Samsca): 2 to 4 hours

Peak effect: Aquaretic and sodium increasing effects (Samsca): 4 to 8 hours

Time to Peak

Plasma: 2 to 4 hours

Duration of Action

Aquaretic and sodium increasing effects (Samsca): 60% peak serum sodium elevation is retained at 24 hours; urinary excretion of free water is no longer elevated

Half-Life Elimination

15 mg doses: 3 hours; ≥120 mg doses: ~12 hours. Note: Half-life increases with higher doses due to a more prolonged absorption.

Protein Binding

>98%

Special Populations: Renal Function Impairment

AUC and Cmax were increased 90% and 10%, respectively, in patients with CrCl <30 mL/minute compared to patients with CrCl >60 mL/minute.

Special Populations: Hepatic Function Impairment

Moderate (Child-Pugh class A and B) or severe hepatic impairment (Child-Pugh class C) decreases the clearance and increases the volume of distribution of tolvaptan.

Use: Labeled Indications

Autosomal dominant polycystic kidney disease: Jynarque, Jinarc [Canadian product]: Slow the progression of kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)

Hypervolemic or euvolemic hyponatremia: Samsca: Treatment of clinically significant hypervolemic or euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and resistant to fluid restriction), including patients with heart failure and syndrome of inappropriate antidiuretic hormone (SIADH).

Limitations of use: Not indicated for use when urgent treatment of hyponatremia is required to prevent or treat serious neurological symptoms. It has not been established that raising serum sodium with tolvaptan provides symptomatic benefit.

Contraindications

Hypersensitivity (eg, anaphylactic shock, generalized rash) to tolvaptan or any component of the formulation; concurrent use with strong CYP3A inhibitors (eg, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin); use in patients unable to sense or appropriately respond to thirst; anuria

Samsca: Additional contraindications: Hypovolemic hyponatremia; urgent need to raise serum sodium acutely; use in patients with ADPKD outside of the FDA-approved REMS

Samsca [Canadian product]: Additional contraindications: Hypovolemic hyponatremia; hypernatremia; urgent need to raise serum sodium acutely; use in patients with ADPKD outside of Health Canada Risk Management Plan (RMP); pregnancy, breastfeeding

Jynarque: Additional contraindications: Patients with a history, signs, or symptoms of significant liver impairment or injury (not applicable to uncomplicated polycystic liver disease); use in patients with uncorrected abnormal blood sodium concentrations; uncorrected urinary outflow obstruction; hypovolemia

Jinarc [Canadian product]: Additional contraindications: Hypovolemia; hypernatremia; clinically relevant hepatic impairment; pregnancy; breastfeeding

Dosing: Adult

Autosomal dominant polycystic kidney disease (ADPKD): Jynarque, Jinarc [Canadian product]: Oral: Initial: 60 mg/day in divided doses (given as 45 mg upon wakening and 15 mg 8 hours later); titrate per response and tolerability at intervals of at least 7 days between titrations to 90 mg/day in divided doses (given as 60 mg upon wakening and 30 mg 8 hours later) followed by 120 mg/day in divided doses (given as 90 mg upon wakening and 30 mg 8 hours later). Maintain urine osmolality of <300 mOsm/kg if possible; if the maximum dose is not tolerated, administration of a lower dose with the goal of achieving urine osmolarity of 250 to 300 mOsm/kg is reasonable (Devuyst 2017).

Hypervolemic or euvolemic hyponatremia: Samsca: Oral: Initial: 15 mg once daily; after at least 24 hours, may increase to 30 mg once daily to a maximum of 60 mg once daily titrating at 24-hour intervals to desired serum sodium concentration. Avoid fluid restriction during the first 24 hours of therapy. Do not use for more than 30 days due to the risk of hepatotoxicity.

Dosage adjustment with concomitant medication:

Moderate CYP3A inhibitors (eg, aprepitant, erythromycin, fluconazole, verapamil):

Samsca: Avoid use.

Jynarque, Jinarc [Canadian product]:

Patients receiving tolvaptan 120 mg/day: Reduce dose to 60 mg/day [45 mg + 15 mg].

Patients receiving 90 mg/day: Reduce dose to 45 mg/day [30 mg + 15 mg].

Patients receiving 60 mg/day: Reduce dose to 30 mg/day [15 mg + 15 mg].

If reduced dose is not tolerated, further dose reduction may be necessary. Interrupt treatment temporarily for short term therapy with moderate CYP3A inhibitors if the recommended reduced doses are not available.

Strong CYP3A inhibitors (eg, ketoconazole, clarithromycin, ritonavir, saquinavir): Samsca, Jynarque: Use is contraindicated.

Strong CYP3A inducers (eg, rifampin, barbiturates, phenytoin, carbamazepine, St John's Wort):

Jynarque, Jinarc [Canadian product]: Avoid use.

Samsca: Avoid use. If concurrent use is necessary, monitor patient response and increase tolvaptan dose as necessary.

P-gp inhibitors (eg, cyclosporine, quinidine): Dose reduction of tolvaptan may be necessary.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment

CrCl ≥10 mL/minute: No dosage adjustment necessary.

CrCl <10 mL/minute: Use not recommended (has not been studied); contraindicated in anuria (no benefit expected).

Dosing: Hepatic Impairment

Samsca: Avoid use in patients with underlying liver disease, including cirrhosis.

Jinarc [Canadian product]:

Preexisting hepatic impairment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution and monitor closely. Avoid initiation of therapy if AST/ALT >3 times ULN. Use is contraindicated in patients with clinically relevant impairment.

Dosage adjustment for toxicity (during therapy): Interrupt therapy if hepatotoxicity is suspected and promptly evaluate hepatic function; upon resolution may consider reinitiating therapy cautiously.

ALT or AST <3 times ULN: Continue therapy cautiously and monitor frequently.

Permanently discontinue for any the following: ALT or AST >8 times ULN, ALT or AST >5 times ULN for >2 weeks, ALT or AST >3 times ULN and total bilirubin >2 times ULN or INR >1.5, ALT or AST >3 times ULN with persistent symptoms of hepatic injury.

Administration

Oral: May be administered without regards to meals. Water should be available at all times during use and patients encouraged to drink to avoid thirst and prevent dehydration from occurring. Interrupt therapy if the ability to drink or accessibility to water is limited.

Samsca: Treatment should be initiated or reinitiated in a hospital.

Nasogastric (NG) tube: Administration via NG tube resulted in an ~25% reduction in AUC and a modest reduction in Cmax in one study; 24-hour urine output was reduced by only 2.8%. Therefore, until further studies are done to determine a bioequivalent dose when administering via NG tube, NG tube administration of a crushed 15 mg tablet appears to be a viable alternative method of administration (McNeely 2012).

Dietary Considerations

Grapefruit juice may increase tolvaptan serum concentrations. Management: Avoid concurrent use with grapefruit juice.

Storage

Jynarque: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).

Samsca: Store at 25°C (77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).

Drug Interactions

Angiotensin II Receptor Blockers: Tolvaptan may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Monitor therapy

Angiotensin-Converting Enzyme Inhibitors: Tolvaptan may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Monitor therapy

BCRP/ABCG2 Substrates: Tolvaptan may increase the serum concentration of BCRP/ABCG2 Substrates. Consider therapy modification

Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible. Monitor therapy

Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Avoid combination

CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Monitor therapy

CYP3A4 Inducers (Strong): May decrease the serum concentration of Tolvaptan. Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed. Avoid combination

CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Tolvaptan. Management: Jynarque dose requires adjustment when used with a moderate CYP3A4 inhibitor. See labeling or full interaction monograph for specific recommendations. Use of Samsca with moderate CYP3A4 ihibitors should generally be avoided. Consider therapy modification

CYP3A4 Inhibitors (Strong): May increase the serum concentration of Tolvaptan. Avoid combination

Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible. If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects). Consider therapy modification

Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Monitor therapy

Desmopressin: Tolvaptan may diminish the therapeutic effect of Desmopressin. Avoid combination

Digoxin: Tolvaptan may increase the serum concentration of Digoxin. Monitor therapy

Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy

Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Avoid combination

GlyBURIDE: Tolvaptan may increase the serum concentration of GlyBURIDE. Consider therapy modification

Grapefruit Juice: May increase the serum concentration of Tolvaptan. Avoid combination

Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Avoid combination

Ivosidenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Monitor therapy

OAT3 Substrates: Tolvaptan may increase the serum concentration of OAT3 Substrates. Consider therapy modification

OATP1B1/SLCO1B1 Substrates: Tolvaptan may increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Consider therapy modification

OATP1B3/SLCO1B3 Substrates: Tolvaptan may increase the serum concentration of OATP1B3/SLCO1B3 Substrates. Consider therapy modification

Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy

P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). Monitor therapy

Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant. Consider therapy modification

Potassium-Sparing Diuretics: Tolvaptan may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Monitor therapy

Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. Monitor therapy

Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Monitor therapy

Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Monitor therapy

Sodium Chloride: May enhance the adverse/toxic effect of Tolvaptan. Specifically, Hypertonic Saline may increase the risk for too rapid of an increase in serum sodium concentrations. Management: This interaction is specific to Hypertonic Saline. Avoid concurrent use of Hypertonic Saline with Tolvaptan. Avoid combination

St John's Wort: May decrease the serum concentration of Tolvaptan. Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed. Avoid combination

Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity. Any CYP3A4 substrate used with stiripentol requires closer monitoring. Consider therapy modification

Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Monitor therapy

Adverse Reactions

>10%:

Central nervous system: Fatigue (14%), dizziness (11%)

Endocrine & metabolic: Increased thirst (12% to 64%)

Gastrointestinal: Nausea (21%), xerostomia (7% to 16%), diarrhea (13%)

Renal: Polyuria (including pollakiuria, 4% to 70%)

1% to 10%:

Cardiovascular: Palpitations (4%), cerebrovascular accident (<2%), deep vein thrombosis (<2%), intracardiac thrombus (<2%), pulmonary embolism (<2%), ventricular fibrillation (<2%)

Dermatologic: Xeroderma (5%), skin rash (4%)

Endocrine & metabolic: Increased serum sodium (2% to 7%), hyperglycemia (6%), hyperuricemia (4%), hypernatremia (≤4%), dehydration (2% to 3%), hypovolemia (2%), diabetic ketoacidosis (<2%)

Gastrointestinal: Gastrointestinal hemorrhage (cirrhosis patients, 10%), dyspepsia (8%), constipation (7%), decreased appetite (7%), abdominal distention (5%), anorexia (4%), ischemic colitis (<2%)

Genitourinary: Urethral bleeding (<2%), vaginal hemorrhage (<2%)

Hematologic & oncologic: Disseminated intravascular coagulation (<2%), prolonged prothrombin time (<2%)

Hepatic: Increased serum alanine aminotransferase (5%)

Neuromuscular & skeletal: Asthenia (9%), rhabdomyolysis (<2%)

Respiratory: Respiratory failure (<2%)

Miscellaneous: Fever (4%)

<1%, postmarketing, and/or case reports: Anaphylactic shock, anaphylaxis, hepatic failure, hepatotoxicity, hyperkalemia, hypersensitivity reaction, increased serum bilirubin, osmotic demyelination syndrome, skin rash

ALERT: U.S. Boxed Warning

Treatment initiation and monitoring (Samsca):

Tolvaptan (Samsca) should be initiated and reinitiated in patients only in a hospital where serum sodium can be closely monitored.

Too rapid correction of hyponatremia (eg, more than 12 mEq/L per 24 hours) can cause osmotic demyelination, resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma, and/or death. In susceptible patients, including those with severe malnutrition, alcoholism, or advanced liver disease, slower rates of correction may be advisable.

Use of tolvaptan for autosomal dominant polycystic kidney disease outside of FDA-approved REMS:

Because of the risk of hepatotoxicity, tolvaptan (Samsca) should not be used for autosomal dominant polycystic kidney disease (ADPKD) outside of the FDA-approved REMS.

Risk of serious liver injury (Jynarque):

Tolvaptan (Jynarque) can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported.

Measure ALT, AST, and bilirubin before initiating treatment, at 2 weeks and 4 weeks after initiation, then monthly for the first 18 months and every 3 months thereafter. Prompt action in response to laboratory abnormalities, signs, or symptoms indicative of hepatic injury can mitigate, but not eliminate, the risk of serious hepatotoxicity.

Distribution program (Jynarque):

Because of the risk of serious liver injury, tolvaptan (Jynarque) is available only through a restricted distribution program under a Risk Evaluation and Mitigation Strategy (REMS) called the Jynarque REMS Program.

Warnings/Precautions

Concerns related to adverse effects:

• CNS effects: Dizziness, asthenia, and/or syncope have been reported when used for autosomal dominant polycystic kidney disease (ADPKD); advise patients to use caution when performing dangerous tasks (eg, driving, operating machinery).

• Hepatotoxicity: Tolvaptan may increase the risk of serious hepatotoxicity, including fatal hepatotoxicity.

- ADPKD patients: Cases of hepatotoxicity have been reported in patients treated for ADPKD generally during the first 18 months of therapy; liver failure resulting in liver transplantation has also been reported. During use, if signs/symptoms of hepatotoxicity develop or if ALT, AST, or bilirubin increase to >2 times ULN, immediately discontinue use, obtain repeat tests promptly within 48 to 72 hours, and continue testing as necessary; if laboratory abnormalities stabilize or resolve, treatment may be reinitiated with increased monitoring as long as ALT and AST <3 times ULN. Do not reinitiate therapy in patients with signs or symptoms of hepatic injury or ALT or AST >3 times ULN, unless there is another reason for liver injury and the liver injury has resolved. Patients with a stable, low baseline ALT or AST that experience an increase >2 times ULN (or an increase less than 2 times ULN) may be experiencing early liver injury; discontinuation of therapy may be necessary and repeat liver tests prior to reinitiation with increased monitoring.

- Hypervolemic or euvolemic hyponatremia patients: Treatment should be limited to 30 days. Avoid use in patients with liver disease (including cirrhosis) since the ability to recover from further liver injury may be impaired. During use, if signs/symptoms of hepatotoxicity develop, discontinue use.

• Hypovolemia/dehydration: Patients should ingest fluids in response to thirst during therapy. Interrupt or discontinue therapy in patients who develop significant signs or symptoms of hypovolemia.

• Serum sodium monitoring/initiating in hospital: [US Boxed Warning]: Samsca: Tolvaptan should be initiated and reinitiated in patients only in a hospital where serum sodium can be closely monitored. Too rapid correction of hyponatremia (ie, >12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma, and death. In susceptible patients (including those with severe malnutrition, alcoholism, or advanced liver disease), slower rates of correction may be advisable. Patients with SIADH, very low baseline, or patients who are fluid restricted during the first 24 hours of therapy may be at greater risk of overly-rapid correction. Avoid fluid restriction during the initial 24 hours of therapy. Discontinue or interrupt therapy if sodium correction is too rapid and consider administration of hypotonic fluids.

Disease-related concerns:

• Hepatic impairment:

- ADPKD patients: Use is contraindicated in patients with significant hepatic impairment or disease (or a history of).

- Hypervolemic or euvolemic hyponatremia patients: Avoid use in patients with liver disease, including those with cirrhosis, since the ability to recover from further liver injury may be impaired. In addition, patients with cirrhosis have a higher risk of gastrointestinal bleeding.

• Hyperkalemia: Reductions in extracellular fluid volumes may cause hyperkalemia. Patients using concomitant medications that may increase potassium levels or with a pretreatment serum potassium >5 mEq/L should be monitored after initiation of therapy.

• Renal impairment: Use is contraindicated in patients who are anuric. In patients with hypervolemic or euvolemic hyponatremia, use is not recommended in patients with CrCl <10 mL/minute; has not been studied and effects of tolvaptan on serum sodium levels is likely lost at very low levels of renal function. In patients with ADPKD, studies have included patients with normal and reduced renal function.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Other warnings/precautions:

• Appropriate use:

- ADPKD patients: Patients most likely to benefit from therapy are those with rapidly progressive disease or those who are developing progressive disease but lack extensive renal damage. Factors associated with rapid progression include large total renal cyst mass for a given age (measured by total kidney volume), chronic kidney disease stage 2 to 3, rapid deterioration of renal function, systemic hypertension or albuminuria.

- Hypervolemic or euvolemic hyponatremia patients: Monitor closely for rate of serum sodium increase and neurological status; rapid serum sodium correction (>12 mEq/L/24 hours) can lead to permanent neurological damage. Discontinue use if rate of serum sodium increase is undesirable; fluid restriction during the first 24 hours of sodium correction can increase the risk of overly-rapid correction and should generally be avoided; not intended for urgent correction of serum sodium to prevent or treat serious neurologic symptoms; it has not been demonstrated that raising serum sodium with tolvaptan provides a symptomatic benefit.

• Limitations of use: SIADH: Limitations to the use of tolvaptan in SIADH may exist due to concerns about safety, such as overly rapid correction of hyponatremia and potential for hepatotoxicity (Spasovski 2014). Based on available evidence, European clinical practice guidelines recommend against the use of vasopressin receptor antagonists in the treatment of hyponatremia in patients with SIADH (Spasovski 2014). Additional data may be necessary to define the appropriate clinical role of tolvaptan in this condition.

• REMS program [US Boxed Warning]: Jynarque: Because of the risk of serious liver injury, tolvaptan is available only through a restricted distribution program under a Risk Evaluation and Mitigation Strategy (REMS) called the Jynarque REMS Program. Prescribers must be certified by enrolling in the REMS program and must inform patients about the risk of hepatotoxicity associated with Jynarque and how to recognize symptoms of hepatotoxicity; patients must be enrolled in the REMS program and follow monitoring requirements; and pharmacies must be certified by enrolling in the REMS program and only dispense to patients authorized to receive Jynarque. Call 1-877-726-7220 or visit http://www.jynarquerems.com for more information.

Monitoring Parameters

Serum sodium concentration, rate of serum sodium increase, serum potassium concentration (if >5 mEq/L prior to administration or receiving medications known to elevate serum potassium); volume status; and/or signs of drug-induced hepatotoxicity (eg, anorexia, fatigue, right upper abdominal discomfort, jaundice, dark urine, itching); neurologic status (at initiation and after titration)

Additional monitoring recommendations: Jynarque: Hepatic function (ALT, AST, and bilirubin) prior to initiation, at 2 and 4 weeks after initiation, monthly for 18 months, and every 3 months thereafter

Additional monitoring recommendations: Jinarc [Canadian product]: Hepatic function testing prior to therapy initiation, monthly for the first 18 months, then every 3 months for 12 months, and then every 3 to 6 months during therapy. Urine osmolality or specific gravity (trough level prior to morning dose); serum uric acid (prior to initiation and as indicated during therapy

Pregnancy Risk Factor

C

Pregnancy Considerations

Adverse events were observed in animal reproduction studies.

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience increased thirst, loss of strength and energy, constipation, dry mouth, polyuria, diarrhea, lack of appetite, or nausea. Have patient report immediately to prescriber signs of fluid and electrolyte problems (mood changes, confusion, muscle pain or weakness, abnormal heartbeat, severe dizziness, passing out, tachycardia, increased thirst, seizures, loss of strength and energy, lack of appetite, urinary retention or change in amount of urine passed, dry mouth, dry eyes, nausea, or vomiting); signs of high blood sugar (confusion, fatigue, increased thirst, increased hunger, polyuria, flushing, fast breathing, or breath that smells like fruit); difficulty speaking; difficulty swallowing; fatigue; confusion; mood changes; abnormal movements; seizures; muscle weakness; dizziness; weight loss; difficulty walking; black, tarry, bloody stools; vomiting blood; or signs of liver problems (dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or jaundice) (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide